$CERS News

Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript

Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year Guidance

Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate

Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est

Cerus Announces William Greenman Ceases As President And CEO, Becomes Executive Chairman Effective July 1, 2026

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M

Cerus Corporation Closes New Debt Facility of Up to $110 Million

Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

BTIG Upgrades Cerus to Buy, Announces $4 Price Target

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corp (NASDAQ:CERS) Surges on Strong Q1 Beat and Raised Guidance

Cerus Q1 2026 Earnings Call Transcript

Cerus Raises FY2026 Sales Guidance from $224.000M-$228.000M to $227.000M-$231.000M vs $242.400M Est

Cerus Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $53.661M Beat $53.167M Estimate

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Signs Four-Year Supply Agreement With Établissement Français Du Sang For INTERCEPT Blood And Platelet Pathogen Inactivation System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer